| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Erica Zamberletti, Tiziana Rubino, Daniela Parolar. The endocannabinoid system and schizophrenia: integration of evidence. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716159. |
this review provides the latest preclinical and clinical breakthroughs on the endocannabinoid system's role in psychotic disorders such as schizophrenia. |
2013-03-25 |
2023-08-12 |
human |
| Erica Zamberletti, Tiziana Rubino, Daniela Parolar. The endocannabinoid system and schizophrenia: integration of evidence. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716159. |
another important aspect in studying the relationship between the endocannabinoid system and schizophrenia is the impact of cannabis consumption on psychotic disorders, especially when this occurs at vulnerable ages such as adolescence. |
2013-03-25 |
2023-08-12 |
human |
| Kimberly J Jenko, Jussi Hirvonen, Ioline D Henter, Kacey B Anderson, Sami S Zoghbi, Thomas M Hyde, Amy Deep-Soboslay, Robert B Innis, Joel E Kleinma. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophrenia research. vol 141. issue 2-3. 2013-03-19. PMID:22910406. |
binding of a tritiated inverse agonist to cannabinoid cb1 receptors is increased in patients with schizophrenia. |
2013-03-19 |
2023-08-12 |
human |
| Tim Karl, Jonathon C Arnol. What does a mouse tell us about neuregulin 1-cannabis interactions? Frontiers in cellular neuroscience. vol 7. 2013-03-01. PMID:23447438. |
here we review the effects of cannabinoids on a mutant mouse model for the schizophrenia candidate gene neuregulin 1 (nrg1). |
2013-03-01 |
2023-08-12 |
mouse |
| David J Castl. Cannabis and psychosis: what causes what? F1000 medicine reports. vol 5. 2013-01-31. PMID:23361396. |
cannabinoids also produce some psychophysiological deficits also known to be present in schizophrenia. |
2013-01-31 |
2023-08-12 |
Not clear |
| Andrea Giuffrida, Alexandre Seillie. New insights on endocannabinoid transmission in psychomotor disorders. Progress in neuro-psychopharmacology & biological psychiatry. vol 38. issue 1. 2012-12-03. PMID:22521335. |
this mini-review provides an update on the contribution of the endocannabinoid system to the regulation of psychomotor behaviors and its possible involvement in the pathophysiology of parkinson's disease and schizophrenia. |
2012-12-03 |
2023-08-12 |
Not clear |
| Joëlle Desfossés, Emmanuel Stip, Lahcen Ait Bentaleb, Olivier Lipp, Jean-Pierre Chiasson, Alexandra Furtos, Karine Venne, Edouard Kouassi, Stéphane Potvi. Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. Frontiers in psychiatry. vol 3. 2012-10-12. PMID:23055987. |
plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the "mirror effect" of schizophrenia. |
2012-10-12 |
2023-08-12 |
Not clear |
| Joëlle Desfossés, Emmanuel Stip, Lahcen Ait Bentaleb, Olivier Lipp, Jean-Pierre Chiasson, Alexandra Furtos, Karine Venne, Edouard Kouassi, Stéphane Potvi. Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. Frontiers in psychiatry. vol 3. 2012-10-12. PMID:23055987. |
theoretically, schizophrenia and sud may share endocannabinoid alterations in the brain reward system. |
2012-10-12 |
2023-08-12 |
Not clear |
| Joëlle Desfossés, Emmanuel Stip, Lahcen Ait Bentaleb, Olivier Lipp, Jean-Pierre Chiasson, Alexandra Furtos, Karine Venne, Edouard Kouassi, Stéphane Potvi. Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. Frontiers in psychiatry. vol 3. 2012-10-12. PMID:23055987. |
the endocannabinoid system has been shown to be impaired in schizophrenia, and recently, our group has shown that schizophrenia patients with sud have elevated peripheral levels of anandamide and oea that do not normalize after 3-month treatment with quetiapine. |
2012-10-12 |
2023-08-12 |
Not clear |
| Carissa M Coulston, Michael Perdices, Antony F Henderson, Gin S Malh. Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use. Schizophrenia research and treatment. vol 2011. 2012-08-31. PMID:22937266. |
cannabinoids for the treatment of schizophrenia? |
2012-08-31 |
2023-08-12 |
Not clear |
| Carissa M Coulston, Michael Perdices, Antony F Henderson, Gin S Malh. Cannabinoids for the treatment of schizophrenia? A balanced neurochemical framework for both adverse and therapeutic effects of cannabis use. Schizophrenia research and treatment. vol 2011. 2012-08-31. PMID:22937266. |
recent studies have found that cannabinoids may improve neuropsychological performance, ameliorate negative symptoms, and have antipsychotic properties for a subgroup of the schizophrenia population. |
2012-08-31 |
2023-08-12 |
Not clear |
| Matthijs G Bossong, J Martijn Jansma, Hendrika H van Hell, Gerry Jager, Erik Oudman, Emi Saliasi, René S Kahn, Nick F Ramse. Effects of δ9-tetrahydrocannabinol on human working memory function. Biological psychiatry. vol 71. issue 8. 2012-08-16. PMID:22341370. |
evidence indicates involvement of the endocannabinoid (ecb) system in both the pathophysiology of schizophrenia and working memory (wm) function. |
2012-08-16 |
2023-08-12 |
human |
| Patrick D Skosnik, Mohini Ranganathan, Deepak Cyril D'Souz. Cannabinoids, working memory, and schizophrenia. Biological psychiatry. vol 71. issue 8. 2012-08-16. PMID:22449262. |
cannabinoids, working memory, and schizophrenia. |
2012-08-16 |
2023-08-12 |
Not clear |
| Stephen M Eggan, Matthew S Lazarus, Samuel R Stoyak, David W Volk, Jill R Glausier, Z Josh Huang, David A Lewi. Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia. Biological psychiatry. vol 71. issue 2. 2012-04-16. PMID:22036037. |
cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger rna expression: implications for schizophrenia. |
2012-04-16 |
2023-08-12 |
Not clear |
| Patrik Roser, Ida S Haussleiter, Hee-Jeong Chong, Christoph Maier, Wolfram Kawohl, Christine Norra, Georg Jucke. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. Psychopharmacology. vol 218. issue 4. 2012-03-26. PMID:21590281. |
inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia. |
2012-03-26 |
2023-08-12 |
Not clear |
| J Michael Bostwic. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clinic proceedings. vol 87. issue 2. 2012-03-26. PMID:22305029. |
pubmed searches were conducted using the following keywords: medical marijuana, medical cannabis, endocannabinoid system, cb1 receptors, cb2 receptors, thc, cannabidiol, nabilone, dronabinol, nabiximols, rimonabant, marijuana legislation, marijuana abuse, marijuana dependence, and marijuana and schizophrenia. |
2012-03-26 |
2023-08-12 |
human |
| Antonio Waldo Zuardi, Fransisco Silveira Guimarães, Jaime Eduardo C Hallak, José Alexandre S Cripp. Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning? Expert review of neurotherapeutics. vol 11. issue 8. 2012-02-02. PMID:21797651. |
is the highest density of cb1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning? |
2012-02-02 |
2023-08-12 |
Not clear |
| Antonio Waldo Zuardi, Fransisco Silveira Guimarães, Jaime Eduardo C Hallak, José Alexandre S Cripp. Is the highest density of CB1 receptors in paranoid schizophrenia a correlate of endocannabinoid system functioning? Expert review of neurotherapeutics. vol 11. issue 8. 2012-02-02. PMID:21797651. |
the precise role of the endocannabinoid system in the pathophysiology of schizophrenia remains far from understood. |
2012-02-02 |
2023-08-12 |
Not clear |
| N Solowij, M Yücel, C Respondek, S Whittle, E Lindsay, C Pantelis, D I Lubma. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychological medicine. vol 41. issue 11. 2012-02-01. PMID:21466751. |
the cerebellum is rich in cannabinoid receptors and implicated in the neuropathology of schizophrenia. |
2012-02-01 |
2023-08-12 |
Not clear |
| G Burillo-Putze, B Climent Díaz, J L Echarte Pazos, P Munné Mas, O Miró, J Puiguriguer, P Darga. [Emergent drugs (I): smart drugs]. Anales del sistema sanitario de Navarra. vol 34. issue 2. 2012-01-23. PMID:21904408. |
spice (a mixture of herbs with synthetic cannabinoids such as jwh-018, jwh-073 and cp 47497-c8) is giving rise to profiles of dependence and schizophrenia. |
2012-01-23 |
2023-08-12 |
Not clear |